Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0 has received CE certification. This marks a significant advancement in the Swiss company’s polymerase chain reaction (PCR) technology.
Optimizing Laboratory Efficiency with cobas 6800/8800 Systems 2.0
The new cobas 6800/8800 Systems 2.0 update represents a major leap forward for Roche’s PCR technology. It offers several enhancements that optimize laboratory resources, reduce downtime, and increase throughput. By consolidating test menus, the system significantly boosts laboratory efficiency, making it a valuable asset for diagnostic facilities.
Upcoming Market Filing in the US
Following the successful CE certification, Roche has scheduled a market filing for the cobas 6800/8800 Systems 2.0 in the US for the next year. This move is expected to expand the reach of Roche’s innovative PCR technology to the American market, further solidifying the company’s position as a leader in diagnostic solutions.-Fineline Info & Tech
